Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

Exclusion Criteria

• •Pregnancy or breastfeeding
• •Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria, anaphylaxis)
• •Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion), Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella (milnacipran)
• •Previous history (within 14 days prior to enrollment) and current use of monoamine oxidase inhibitors
• •Concomitant use of strong CYP2D6 inhibitors such as delavirdine, paroxetine, fluoxetine, quinidine
• •Pre-existing sustained severe hypertension (BP ≥ 140/80 mmhg in the sitting position)
• •Impaired hepatic function (aspartate amino transaminase \[AST\] and/or alanine amino transaminase \[ALT\] \>2 x upper limit of normal range)
• •Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)
• •Myocardial infarction within 6 months prior to enrollment
• •Congestive heart failure (LV hypertrophy acceptable)
• •History of serious neurologic disease such as cerebral hemorrhage, or stroke
• •Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, unlikelihood of completing the study, and mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study
• •Narrow-angle glaucoma